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Abstract
Background: Signal transduction through the hydrolysis
of glycosyl-phosphatidylinositol (GPI) leading to the re-
lease of the water-soluble inositol phosphoglycan (IPG)
molecules has been demonstrated to be important for
mediating some of the actions of insulin and insulin-like
growth factor-I (IGF-I).
Materials and Methods: In the present study, GPI from
grass pea (Lathyrus sativus) seeds has been puriﬁed and
partially characterized on the basis of its chromatographic
properties and its compositional analysis.
Results: The results indicate that it shows similarities 
to GPI previously isolated from other sources such as 
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rat liver. IPG was generated from L. sativus seed GPI 
by hydrolysis with a GPI-speciﬁc phospholipase D
(GPI-PLD). This IPG inhibited protein kinase A (PKA)
in an in vitro assay, caused cell proliferation in ex-
planted cochleovestibular ganglia (CVG), and decreased
8-Br-cAMP–induced phosphoenolpyruvate carboxyki-
nase (PEPCK) mRNA expression in cultured hepatoma
cells.
Conclusions: Our data indicate that L. sativus seed IPG
possess insulin-mimetic activities. This may explain why
L. sativus seeds have been used in some traditional medi-
cines to ameliorate diabetic symptoms.
Introduction
Glycosyl-phosphatidylinositol (GPI) lipids have a
structural role as protein anchors to the outer cell
surface (1,2). In addition, they are implicated in
hormone, growth factor, and cytokine signal trans-
duction (2,3). Their phosphodiesteric hydrolysis,
mediated by an activated phospholipase, results in
the generation of low-molecular-weight, water-
soluble oligosaccharide species termed inositol
phosphogylcans (IPGs). IPGs have been demon-
strated to possess biological properties when
added exogenously to cells, in many cases mim-
icking the biological effects of hormones and
growth factors such as insulin and insulin-like
growth factor I (IGF-I) (3,4). Distinct IPG species
have been puriﬁed and characterized from a variety
of animal sources. The best characterized of these
is that from rat liver (2,3). Despite the relative ease
of IPG puriﬁcation, a suitable biological source of
IPG is still to be found that would comply with 
the following criteria: (i) high yield of biologi-
cally active IPG, (ii) low cost of puriﬁcation, and
(iii) abundance of starting material. These three
criteria are considered essential for the large-scale
preparation of IPG species.
Diabetes is a chronic and presently incurable
disease that affects an ever-growing proportion of
the world’s population. In spite of the modern ad-
vances in drug design to alleviate and delay the
symptoms of diabetes, there still remains some in-
terest in the use of nonregistered concoctions that
originate from plant origin. Such plants including
Medicago sativa (5), Ginkgo biloba (6,7), Bryonia alba
(8,9), Burmelia sartorum (10), and others (11,12) have
been considered to have “anti-diabetic properties.”
The preparation of extracts from these plants has
been poorly documented and one would envisage
such preparations would be subject to signiﬁcant
variation depending both on geographic location
and the method used. Some of the compounds
within these preparations might be putative IPG
molecules. However, all these reports lack com-
pelling evidence regarding the exact chemical com-
position, structure, and mechanism of action of the
preparations. Grass pea (Lathyrus sativus) is a part of
traditional culture in rural Spain. Eating L. sativus
seeds has been a popular remedy to improve the
condition of diabetic patients and as a general tonic
in Andalusia and the Canary Islands (13). On the
basis of our experience both in the area of IPG 
puriﬁcation and assessment of its biological proper-
ties and the above considerations regarding the
search for a suitable source of IPG, we started this
study to determine the presence of IPG in L. sativus
seeds with the objective of characterizing for the
ﬁrst time plant-derived IPG-like molecules.
Materials and Methods
Materials
L. sativus seeds were from the C.R.F.-I.N.I.A. col-
lection (Madrid, Spain). [32P]ATP and [32P]dCTP
(speciﬁc activities 3000 Ci/mmol) were purchased
from Little Chalfont, Amersham, UK. Fetal bovine
serum (FBS), cell culture media, and supplements
were purchased from GibcoBRL (Paisley, UK). Silica
gel thin layer chromatography (t.l.c.) plates were
purchased from Merck (Darmstadt, Germany). Au-
thentic lipid standards, histone IIA, PKA, orcinol,
and the molybdenum blue reagent were purchased
from Sigma (Poole, UK). A murine monoclonal anti-
proliferative cell nuclear antigen (PCNA) antibody
was obtained from ATOM (Barcelona, Spain). Phos-
phatidylinositol-speciﬁc phospholipase C (PI-PLC),
from Bacillus cereus, was purchased from Molecular
Probes (Leiden, The Netherlands). GPI-speciﬁc
phospholipase C (GPI-PLC), from Trypanosoma brucei,
was bought from Oxford Glycosystems (Oxford,
UK). GPI-speciﬁc phospholipase D (GPI-PLD) was
puriﬁed from bovine serum as reported (14). Other
reagents were of analytic grade or better and were
from Merck.
Methods
PURIFICATION OF L. sativus SEED GPI. GPI was puri-
ﬁed as detailed (15). Brieﬂy, total lipids isolated by
CHCl3/MeOH/HCl extraction of 50 g of L. sativus
seeds were adsorbed onto silica G60. The contami-
nants were removed ﬁrst with chloroform and then
the pellet from a 2800 g spin was washed three
times in a chloroform:methanol:HCl (300:50:3) so-
lution. Polar lipids were extracted by washing the
silica with methanol. This extract was applied to
the origin of heat-activated t.l.c plates. The plates
were then developed twice in the acidic solvent
consisting of CHCl3/CH3COCH3/MeOH/CH3COOH/
H2O (10/4/ 2/2/1, by volume). The material remain-
ing at the origin (from 0.5 cm below to 1 cm
above) was eluted from silica by washing three
times with methanol. The eluted material was dried
under a gentle steam of nitrogen gas before it was
applied to a further set of t.l.c. plates for develop-
ment in the basic solvent consisting of CHCl3/
MeOH/16M NH3/H2O (45/45/3.5/10, by volume).
GPI comigrated with a rat liver GPI standard and
was located between the authentic standards phos-
phatidic acid (PtdOH) and phosphatidylcholine 
(PtdCho). GPI was eluted from silica by washing
three times with methanol. The eluted material was
passed through a 0.22-m nylon ﬁlter to remove sil-
ica before drying under a gentle steam of N2. GPI
was stored dry under N2 at 80C. Conﬁrmation
that GPI was indeed the lipid migrating at the
stated position was achieved by noting its reaction
with I2 vapor, Coomassie blue (both general lipid
stains), ninhydrin (a stain for free amino groups),
molybdenum blue reagent (a stain for phospholipid
phosphate), and orcinol/sulphuric acid (a stain for
sugar residues). Free amino and phosphate groups
within the eluted GPI were estimated as previously
described (15). The stoichiometry of sugar residues
within GPI was determined using orcinol/ sul-
phuric acid with reference to authentic synthetic
IPG analog standards (16,17). To determine the 
fatty acid composition of the puriﬁed GPI, gas 
chromatography-mass spectrometry (GC/MS) was
used as previously described (18). GPI was also 
puriﬁed from rat liver (15).
HYDROLYTIC SUSCEPTIBILITY OF L. sativus SEED GPI BY
PHOSPHOLIPASES. Puriﬁed L. sativus seed GPI was re-
constituted asymmetrically into preformed liposo-
mal membranes according to previously published
methods (18,19). GPI-PLD, GPI-PLC, and PI-PLC
were employed in the incubations. The speciﬁcity of
the enzymes has been reported (18–20). The per-
centage of GPI hydrolyzed was determined as 
previously described (18,19). The upper aqueous-
methanolic phase formed after termination of the
GPI hydrolysis incubation with GPI-PLD was lyo-
philized. The amount of IPG generated was de-
termined by measuring the inorganic phosphate and
amino groups within this fraction (18,19). The per-
centage of GPI hydrolysis was approximately 90%.
IPG was ﬁlter sterilized into Hank’s salts solution for
testing biological activity. Until use, it was either
stored lyophilized or in solution at 80C. Rat liver
IPG (rIPG) was also prepared, quantiﬁed, and stored
using the above method.
BIOLOGICAL ASSAYS. The ability of the IPG to inhibit
the activity of protein kinase A (PKA) was assessed
by using a previously published method (21).
Explanted cochleovestibular ganglia (CVG) were
isolated from chicken embryos (embryonic day 3) as
described (22). Organotypic cultures of CVG were
treated with IPG and rIPG at different concentra-
tions as previously described (23). IPG-induced cell
proliferation was assessed using two methods: by
morphometric analysis of the CVG after 24-hr
treatment with IPG and by the expression of the
PCNA, a 36-kDa nuclear protein essential for DNA
synthesis and cell-cycle expression, by Western
blotting (a 1:500 dilution was used) as previously
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sulphuric acid, which reacts with sugar residues 
(results not shown). This multiple t.l.c. method has
been proven to separate GPI from all neutral lipids
and all other phospholipid classes (including the
polyphosphoinositides, which may be contaminants
after the ﬁrst round of t.l.c.). Identical t.l.c. migration
described (24–26). A secondary antibody conjugated
to peroxidase was purchased from Bio-Rad (Her-
cules, CA, USA) and was used according to the 
supplier.
RNA Extraction and Northern Blot Analysis of PEPCK
This followed a previously published method 
(27). Brieﬂy, H35 cells were routinely grown in
Dulbecco’s Modiﬁed Eagles Medium with 10% FBS,
2 mM of L-glutamine, 100 U/ml of penicillin, and
100 g/ml of streptomycin at 37C in a water-
saturated atmosphere containing 5% CO2. After 
24 hr of serum starvation, cultures of H35 cells 
were incubated in the presence of 8-Br-cAMP for 
5 hr. Saline (control), insulin, rIPG, or IPG were
added to the medium for the last 2 hr of 8-Br-cAMP
treatment. Total H35 cell RNA was isolated by the
guanidinium-thiocianate-phenol-chloroform extrac-
tion method (28). Total RNA (20 g per sample) was
size fractionated by electrophoresis in a 1.2%
agarose gel under denaturing conditions (1.1 M of
formaldehyde in MOPS buffer) and transferred to
nitrocellulose ﬁlters (Schleicher and Shuell, Dassel,
Germany). Prehybridization and hybridization of
membranes were performed under moderate strin-
gency conditions (50% formamide at 42C) for 5 
and 24 hr, respectively. Filters were hybridized with
a phosphoenolpyruvate carboxykinase (PEPCK)
probe. The probe was labeled with [32P]dCTP by the
random priming method according to the manu-
facturer’s instructions (Amersham). Blots were 
hybridized with the PEPCK probe and exposed to 
x-ray ﬁlm for 3 days at 70C. The relative amounts
of RNA loaded in each lane were visualized by stain-
ing the gel with ethidium bromide. Quantitation
was performed by scanning densitometry of the 
x-ray ﬁlm using the NIH 1.62 program on an Apple
Macintosh computer.
Data Presentation
Unless speciﬁed otherwise, data are presented as
representative results from at least three indepen-
dent experiments.
RESULTS AND DISCUSSION. To determine if L. sativus
seeds contained GPI-like molecules, we employed
established protocols that have been used for the
extraction of GPI from mammalian tissues and cul-
tured cell lines (15). After two consecutive rounds of
t.l.c., a lipid that comigrated with rat liver GPI
between the phospholipid standards PtdCho and
PtdOH was identiﬁed as a phospholipid based on
the following considerations: (i) that it was able to
be stained with I2 vapor, (ii) that it was able to be
stained with Coomassie blue, and (iii) that it reacted
positively with a molybdenum spray reagent which
is speciﬁc for compounds containing phosphate
groups (Fig. 1). In addition, we were able to stain
the phospholipid with ninhydrin, a speciﬁc reagent
that reacts with free amino groups and with orcinol/
Fig. 1. Visualization of L. sativus seed GPI on t.l.c. plates.
Puriﬁed GPI was applied to t.l.c. plates which were developed
in the basic solvent system (see Materials and Methods).
(A) GPI stained with I2 vapor. (B) GPI stained with Coomassie
blue. (C) GPI stained with molybdenum blue reagent.
Table 1. Fatty acid composition of L. sativus seed
and rat liver GPI.
% of Total Fatty Acids















14:0, 14-carbon chain length fatty acid without a single carbon–
carbon double bond; n, position of the ﬁrst carbon–carbon double
bond in the fatty acid.
ND, not detected.
C. Pañeda et al.: A New Insulin-Mimetic Compound From Plants 457
and chemical staining of rat liver GPI was observed
when run in parallel (results not shown). Such t.l.c.
behavior together with the positive staining led us
to tentatively identify the spot as a putative GPI-like
molecule. The sugar to phosphate to free amino
group stoichiometry of the putative L. sativus seed
GPI was estimated to be in a ratio of 3:2:1. This
indicated that the L. sativus seed GPI was less phos-
phorylated than rat liver GPI (15).
To further characterize the structure of the puta-
tive L. sativus seed GPI, we decided to determine 
its fatty acid composition. Transmethylation of the
fatty acids converted them into their corresponding
methyl esters. GC/MS revealed that the major fatty
acids were palmitic (16:0), stearic (18:0), and ligno-
ceric (24:4) acids together making up approximately
82% of total. Other fatty acids (containing saturated,
monounsaturated, and diunsaturated structures)
represented minor species (Table 1). When rat liver
GPI was analyzed in parallel, a very limited set of
fatty acid methyl esters were generated. In rat liver
GPI, the major fatty acids were also saturated ones,
16:0 and 18:0 together making up approximately
90% of total. The only monounsaturated fatty acid
found was oleic acid (18:1n-9)(2.5% of total). Possi-
ble contamination of the putative L. sativus seed GPI
or rat liver GPI with polyphosphoinositides was
ruled out due to the fact that no polyunsaturated
(e.g., arachidonic) fatty acid methyl esters were
identiﬁed. The analysis indicated that in general
terms the fatty acid composition of the putative 
L. sativus seed GPI was similar to that of rat liver 
GPI, suggesting some common biosynthetic and/or
functional requirements.
One of the key features of GPI phospholipids is
their susceptibility to hydrolysis by phospholipases
(15,18–20). Additional support for our claim that the
putative L. sativus seed GPI was indeed a free GPI
was strengthened by the ﬁnding that GPI-PLD, 
PI-PLC, and GPI-PLC caused the hydrolysis of the
putative L. sativus seed GPI (Table 2). Of the three
phospholipases used, GPI-PLD showed the great-
est hydrolytic activity when the putative L. sativus
seed GPI was incorporated into liposomes consist-
ing of phosphatidylethanolamine (PtdEth), PtdCho, 
and cholesterol (Ch). The upper aqueous-methanolic
phase formed after termination of the GPI hydroly-
sis incubation with GPI-PLD was lyophilized and
both its phosphate and amino group content were
estimated. This putative IPG showed a sugar to
inorganic phosphate to amino group stoichiometry
of 3:1:1. L. sativus seed GPI was a better substrate for
the three enzymes than rat liver GPI (18). Together,
our data on chemical composition and susceptibility
to hydrolysis may suggest that seed GPI was a better
substrate for phospholipases because it was less
phosphorylated than rat liver GPI. Indeed, GPI-
speciﬁc phospholipases and bacterial PI-PLC are spe-
ciﬁc for PI and GPI showing no or little activity
toward PIPs (reviewed in 1,3).
To determine if the polar headgroup of GPI, the
IPG, was generated as a consequence of the action of
GPI-PLD on the seed GPI, we studied the biological
activities corresponding to IPG. The inhibition of
PKA activity in an in vitro assay has been the typical
assay for the detection and assessment of the biolog-
ical activity of IPG (21). We found that 5 M of IPG
caused an inhibition (approximately 23%) of PKA
Table 2. Hydrolysis of L. sativus seed GPI by phospholipases C and D.
Rate Hydrolysis Hydrolysis Hydrolysis Hydrolysis Hydrolysis
Liposomal Lag time (nmol GPI/ (%GPI) (%GPI) (%GPI) (%GPI) (%GPI)
Composition (min) min) 10 min 15 min 60 min 60 min 60 min
GPI/PtdCho/PtdEth





0.33mMa 32 21 14
GPI/PtdEth/PtdCho/Ch
(8:46:23:23)
0.33mMa 0.53 0.35 0.23
L. sativus seed GPI was reconstituted in liposomal membranes and then incubated with either GPI-PLD, GPI-PLC, or PI-PLC. 
aAll liposome preparations contained 13 g GPI at the start. The SEM showed 10% variation.
Enzyme
GPI-PLD PI-PLC GPI-PLC
Fig. 2. Biological effects of the L. sativus seed IPG. (A) The
ability of IPG and rIPG to inhibit the activity of PKA in an 
in vitro assay. *Taken from Villalba et al. (21). (B) The effect of
no additions, IPG (10 M), rIPG (10 M) or IGF-I (1 nM) on
the growth of organotypic cultures of CVG. The calibration bar
represents 100 m. The numbers below each photograph repre-
sent CVG volume measurements (arbitrary units). (C) Upper:
Western blot detection of PCNA expression within the CVG 
after treatment with no additions, IPG (10 M), rIPG (10 M)
and IGF-I (1 nM). Lower: Densitometric analysis of the band
corresponding to PCNA. IPG was obtained by hydrolysis of 
L. sativus seed GPI with GPI-PLD.
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incubation, the size of the CVG increased more 
than 2-fold (Fig. 2B). As expected and previously
reported, incubation of CVG with IGF-I resulted in
growth of the CVG (over 3-fold) (Fig. 2B). Interest-
ingly, the effect of IPG was almost as powerful as
IGF-I in the promotion of growth of the CVG. To
provide evidence that the growth of the CVG was
accompanied by changes in molecular markers, the
expression of the PCNA was monitored by Western
blotting (24–26). In Figure 2C, the detection of
PCNA is shown. Densitometric scanning of the
bands corresponding to the PCNA revealed that its
intensity correlated with the increases in volume of
the CVG (Fig. 2B) after treatment with IPG, rIPG,
and IGF-I. As expected, treatment of the CVG with
IGF-I led to an increase in the expression of PCNA
(over 4-fold), greater than that of IPG (nearly 3-fold)
and rIPG (approximately 2-fold). Using both mor-
phometric analysis of organotypic explants and
Western blotting detection of the PCNA (Figs. 2B
and 2C, respectively), we found that L. sativus seed
IPG was slightly more active than rIPG. We do not
yet have a full explanation for this observation.
However, it is most likely that structural differences
within the glycan structure of the IPG exist that may
determine their biological activities, as indicated by
studies with synthetic analogs (31).
Of all the growth factors and hormones known
to cause the generation of IPG, insulin has been by
far the most well documented (1,3,4). One of the key
factors for the characterization of IPG molecules is
their ability to mimic certain metabolic effects of in-
sulin. One of these metabolic effects is the reversal
of 8-Br-cAMP–elevated PEPCK mRNA expression
(27,32). We decided to test whether L. sativus IPG
had insulin-mimetic properties by using this exper-
imental model. When the 8-Br-cAMP–treated H35
hepatoma cell line was treated with insulin, a 
decrease (of approximately 70%) in the level of
PEPCK mRNA was observed (Fig. 3). When rIPG
and IPG were used in place of insulin, a smaller de-
crease (approximately 35%) in the level of PEPCK
mRNA was observed in both cases. These results 
are in agreement with those previously published
(27,32), and suggest that IPG prepared from human
liver, rat liver, and L. sativus seed show similar in-
sulin-mimetic activity.
Homeopathic extracts and infusions of plant ma-
terial have long been used to try to reduce diabetic
symptoms. However, the validity and compositional
analysis of these treatments remain to be ascer-
tained. One example is the antihyperglycemic agent
3-O-methyl D-chiro-inositol (pinitol) (33). This com-
pound has been suggested to form part of the struc-
ture of a bovine liver-derived IPG (34). Further-
more, pinitol has been found to be present in 
the leaves of Bougainvillea, a plant that has been
used to treat diabetes mellitus in India (35) and in
gymnosperms and angiosperms (36). The novel gly-
coside 1D-2-O--D-galactopyranosyl-chiro-inositol
activity, similar to that seen with 10 M of rIPG pre-
pared in an identical manner. When the concentra-
tion of IPG was increased to 10 M, the observed
inhibition was over 50% (Fig. 2A). These initial 
results indicate that biologically active IPG was gen-
erated after GPI-PLD–mediated hydrolysis of the pu-
tative L. sativus seed GPI.
Previous work from our laboratory demon-
strated that the developing inner ear of the chicken
embryo is a suitable model to study growth factor–
regulated proliferation and differentiation. IGF-I
promotes growth, survival, and neurogenesis in both
the otic vesicle and the CVG, which form part of the
developing inner ear, in part through the GPI/ IPG
signaling system (23,26,29,30). In organotypic cul-
tures of CVGs, IPG was able to increase the size of
the CVG by almost 3-fold (Fig. 2B). When an iden-
tical concentration of rIPG was used in a parallel 
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has been found in the beans of the jojoba plant 
Simmondsia chinensis (37). This compound shows
some similarity to that of the structure of the pro-
posed bovine liver-derived IPG. According to Fonte-
les et al. (33), the bovine liver–derived IPG con-
tained a chelated transition metal. This was suggested
to be manganese. In an extract of lucerne (Medicago
sativa), used as an antihyperglycemic agent in South
Africa, a high level of manganese was found (38).
Whether this extract also contained IPG-like mole-
cules still remains to be determined.
In summary, we have characterized a putative
GPI phospholipid in L. sativus seeds that shows iden-
tical chromatographic and hydrolytic properties to
those of GPI isolated from rat liver. Second, we have
been able to demonstrate that the hydrolysis of the
putative GPI phospholipid by GPI-PLD generates an
IPG that shows in vitro inhibition of PKA activity
and in vivo insulin-mimetic biological properties. 
Together, the results suggest that there are free GPI
molecules in L. sativus seeds with properties very 
similar to those previously described in mammals.
Further analyses of lipid and non-lipid extracts of 
L. sativus seeds will be necessary to substantiate
whether they have antihyperglycemic properties. If
such biochemical and pharmacologic criteria are
met, then L. sativus seeds could be exploited for the
puriﬁcation of compounds, including IPG, which
may help to design new agents to combat insulin-
resistant diseases.
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